RegulatoryAug 4, 2026, 04:14 PM
Mangoceuticals Gets Nasdaq Bid Price Extension Until Feb 2027
AI Summary
Mangoceuticals, Inc. received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company's common stock had traded below $1.00 for 30 consecutive business days, leading to an initial deficiency notice on February 4, 2026. The new deadline to meet the $1.00 bid price requirement is February 1, 2027, with the company indicating it may use a reverse stock split if needed. This extension provides flexibility as the company progresses with its business combination agreement with Nuclea Energy Inc.
Key Highlights
- Received Nasdaq deficiency notice on Feb 4, 2026, for common stock bid price below $1.00.
- Initial compliance period of 180 days expired on Aug 3, 2026.
- Granted an additional 180-day extension by Nasdaq until Feb 1, 2027.
- Extension based on meeting other listing requirements and intent to cure via reverse stock split if necessary.
- The extension does not affect current listing or trading of the common stock.
- Company is advancing a definitive business combination agreement with Nuclea Energy Inc.
Price Impact
More from MGRX